Top Medicare prescribers rake in speaking fees from drugmakers
When the blood pressure drug Bystolic hit the market in 2008, it faced a crowded field of cheap generics. So its maker, Forest Laboratories, launched a promotional assault on the group in the best position to determine Bystolic's success: those in control of prescription pads. It flooded the offices of health professionals with drug reps, and it hired doctors to persuade their peers to choose Bystolic ? even though the drug hadn't proved more effective than competitors. The strategy worked. In the 2012 fiscal year, sales of Bystolic reached $348 million, almost double its total from two years earlier, the company reported.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- PCI: Concerns Mount About Appropriateness
- Transforming Cancer Care
- MA an Insurance Proving Ground for Providers
- Targeting Self-Insured Populations